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ABSTRACT 
Long term stability is done in a matrix approach after manufacturing of drug for ensuring the stability of drugs. Using the matrix basic design 
which is useful for testing 3 lots under one storage condition can be expanded to multiple presentation of products or multiple storage 
conditions. The design shows full testing at the end points (0 and 36 months) and shows partial testing at the interim time points (3, 6, 9, 12, 18 
&24 min). With the assistance of a statistical search algorithm, the test points are selected . 37.5%  reduction in analytical testing, while 
permitting a reliable interim expiry estimate. Based on 12 months stability data it is provided by the proposed matrix design. The matrix 
approach obtained by expiration dating periods is typically more conservative than the approaches derived from the full testing estimate. The 
comparison of expiration dating estimate for meter dose inhaler and capsules is presented using the matrixed and full testing approaches. 
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Introduction:[1] 
Stability studies were managed to exhibit how the quality of 
drug substances varies with time under the capacity of 
different environmental factors like temperature, humidity , 
light etc to initiate and re-examine the drug substance to 
recommend strong conditions . the drug product is defined 
as the dosage form in the final package .stability studies 
must be applicable to all strengths and all packages. For new 
drug product accelerated testing is necessary for six months 
and long term testing is required to determine the shelf life . 
thus the cost of stability studies is essential leading to 
statistically designed stability studies ,which are called 
matrix design where “ a selected  subject total number of 
possible samples for all combinations is tested at a specified 
time point  
History: 
Statistically in early 1980s designed stability studies were 
first used (E.Nordbrock,1981, stability protocols) and  it was 
accepted by US food and drug 
administration.(W.Fairweather,1982,personal 
communication). Nakagaki[4], who was first person to use 
the terminologies matrix and bracket[9-28]. Nordbrock[2,3,5] 
was the one who appeared in first journal articles in 1992[6-
8].Bracketting and matrixing guidance was issued in 
2003[29].A guidance on evaluation of stability data was 
issued in 2004[30]. 
Designs: 
Background 
Basic analysis which is applied to stability data is linear 
regression of the parameter of the time therefore the 
selection of observations in the slope is to take first half in 
beginning of the study which gives the minimum variance 
and second half is at the end. The statistically designed 
stability designs are analysed for several times either they 
can be during the new drug product or either can be yearly 
for market product. 
Basic Matrix 2/3 on Time Design  
For one dosage form the strength has to be studied for long 
term study. In a single package there are three batches, 
which should be tested for every three months in first year 
and for every six months in second year. Later they must be 
tested annually that is yearly once until the expiry date 
period. Thus the shelf life of the period must be thirty six 
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months so that for complete study can be done, so each of 
the three batches was tested at 0,3,6,9,12,18,24 and 36 
months(Table 1). This matrix 2/3 time design can be tested 
only for the intermediated time points that are designed 
only for two of the three batches. This design can be tested 
for 18 months in all batches  
 
Table. 1: Basic Matrix 2/3 on Time Design 
Batch                                                                                                             Test Times          
A                                                                                                                  0,3,9,12,24,36 
B                                                                                                                  0,3,6,12,18,36 
C                                                                                                                  0,6,9,18,24,36 
 
Matrix 2/3 on Time Design With Multiple Package  
In this designed a single strength is packed unto three 
packages with equal balance in each of three packages. 
Balance means each batch have been tested twice at 
intermediate time point and analysis will be done after 
completion of eighteen months .These design can be 
modified by telling all package combinations at 18 
months(Table 2). 
 
Table 2 Matrix 2/3 on Time Design With Multiple Package 
Batch                       Pkg 1                                Pkg 2                                       Pkg 3                                    
A                                 T1                                     T2                                            T3 
B                                  T2                                     T3                                           T1 
C                                  T3                                     T1                                           T2 
Pkg 1= package 1, etc 
 
Matrix 2/3 on Time Design with Multiple Packages and 
Multiple Strengths  
Further extension of the above is the three strengths are 
manufactured using same formula with different weights 
and divided into 9 sub batches and each strength consists of 
3 packages. This design is applied for 9 sub batches in 
balanced fashion. Each sub batch at the intermediate time 
point is tested twice in such a manner that each batch is 
tested 6 times during this intermediate interval and the 
analysis is done after 18 months. By testing all batches by 
strength by package combinations these design can be 
modified at 18 months(Table 3).  
 
Table 3 Matrix 2/3 on Time Design with Multiple Packages and Multiple Strengths 
Batch                Strength              Pkg 1                        Pkg 2                                   Pkg 3                                    
A                               10                       T1                             T2                                        T3 
A                               20                       T2                             T3                                        T1 
A                               30                       T3                             T1                                        T2          
B                               10                        T2                             T3                                        T1     
B                               20                        T3                             T1                                        T2 
B                               30                        T1                             T2                                        T3 
C                               10                        T3                             T1                                        T2 
C                               20                        T1                             T2                                        T3 
C                               30                        T2                             T3                                        T1 
Pkg 1= package 1, etc 
Table 4 Test Code Definitions 
Batch                                                                            Test Times after Time 0 
T1                                                                                        3,9,12,24,36 
T2                                                                                        3,6,12,18,36                                           
T3                                                                                        6,9,18,24,36 
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Matrix 1/3 on Time Design: 
The design forms are reduced from 2/3 to 1/3 by reduction 
in amount of testing. For example  one of the 3 batches are 
tested during intermediate time point during basic 1/3 time 
design and analysis is done after 18 months . these basic 1/3 
design can be further modified by testing several batches at 
the time of completion of 18 months.(Table 5)
 
Table 5 Matrix 1/3 On Time Design 
Batch                                                                                                           Test Times          
A                                                                                                                  0,3,12,36 
B                                                                                                                  0,6,18,36 
C                                                                                                                  0,9,24,36 
 
Matrix on Batch ×Strength×Package Combination: 
This design is done for multiple strengths and multiple 
packages. To test the batch only single portion of  the batch –
by –strength by package combinations  are taken . for 
example ; in 3 batches it is divided to two strengths giving 6 
sub batches, the batch size is  small and only 2 packages  can 
be manufactured in each sub batch . The design should be 
balanced because each of 2 packages of sub batch are 
tested(Table 6). 
 
Table 6 Matrix on Batch ×Strength×Package Combination 
Batch                  Strength              Pkg 1                        Pkg 2                                   Pkg 3                                    
A                               10                       T1                             T2                                        - 
A                               20                       T2                             -                                          T1 
B                               10                        T2                             -                                          T1 
B                               20                        -                                T1                                       T2 
C                               10                        -                                T1                                       T2 
C                               20                        T1                             T2                                        - 
Table 7 Test Code Definitions 
Batch                                                                            Test Times after Time 0 
T1                                                                                        3,9,18,36 
T2                                                                                        6,12,24,36                                           
 
Uniform Matrix Design 
Another type of design is uniform matrix design “ the same 
time protocol is used for all combinations of the other design 
factors.” This testing is done only during 12 ,24 and 36 
months. Advantage of this study design is this design is more 
simplified  with  reduced variability of slope of the 
regression line. Disadvantage is major stability problems . 
therefore this model is not acceptable majority of  areas. 
Analysis Background [30] 
Long term based data the ich q1e guidance for single 
package and single strength specifies that  95% one sided 
lower confidence bound for the mean regression line must 
be according to ich q 1 e . in case of multiple strengths / 
multiple packages there are three possible approach for 
analysis 
 the  first approach : package by strength combination 
separately  
second approach : all data to model with one analysis with  
separate intercepts  and slopes for each batch by its strength 
and package  without  poolability testing  
third approach: model all data with one analysis and test for 
probability for selection of appropriate reduced model. 
Separate Analysis Approach 
Multiple analysis are conducted in first approach ,with 
separate analysis of each package- by-strength-by batch. For 
each of separate analyses shelf life is calculated and product 
shelf life minimum of all package by strength by batch  shelf 
lives.  
One Analysis Approach, Without Testing Poolability 
It is a second approach, out of which one analysis is done 
that includes complete data by using individual intercepts a 
shelf life is estimated and pooled mean square error from 
the entire set. Shelf life for each batch by package by 
strength is taken as the time the batch by  package by 
strength acceptable within limits .For multiple batches only 
one package and one strength the SAS model is 
                    
Where B is a class term for batch A is covariate for age .For 
multiple batches and multiple packages only one strength. 
SAS model is  
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Where B is class term for batch ,p is class term for package 
and A is the covariate for age . This model consist of separate 
slopes for every batch by package . The shelf life of the 
product is the minimum of all batch by package shelf lifes. 
One Analysis: Testing Poolability[14,27,28] 
It is very important that full model reflects manufacturing 
process. For exact formulation by using different weights it 
is assumed that there are multiple strengths and multiple 
packages so granulation batches split into sub batches, 
where it is manufactured into a different strength of the 
product using different weights of granulation . Zero 
samples are collected from each sub batch of the tablet and 
every tablet is  packaged into sub batch products. Process 
validation provides proof that entire tablet sub batch is 
uniform  
SAS model is  
 
With B as a class term for granulation batch, 
P= package 
S= strength 
A= covariate for time 
This model testing begins the slope two  way interactions 
determine by using a significance level of 0.25 when the 
batch is a part of the term and 0.05 otherwise .By using final 
model 95% one sided lower confidence bound to mean 
regression line and shelf life is assigned for each package by 
strength. 
Factors Acceptable To Matrix 
 It is acceptable for NDA 
 Investigational new drug application studies 
 Supplements and marketed products  
 It is acceptable to matrix for product such as solids 
 It is acceptable to matrix for product such as 
semisolids 
 It is acceptable to matrix for product such as liquids 
 It is acceptable to matrix for product such as aerosols 
 It is acceptable to matrix after bracketing 
 It is acceptable to matrix when there are multiple 
sources of raw material 
 It is acceptable to matrix if there are multiple sites of 
drug product manufacture 
 It is acceptable to matrix when identical formulations 
are manufactured into several strengths  
 It is acceptable to matrix if formulation are cosely 
related  
 Matrixing is applicable to the orientation of container 
during storage 
 Matrixing may be applicable to in certain cases when 
closely related formulations are used in different 
strengths  
 Matrix across container and closure systems may be 
applicable if justified  
 It is acceptable to matrix within a package composition  
 It is not acceptable to matrix across storage conditions  
 It is not acceptable to matrix across parameters , such 
as dissolution and potency 
General Rules 
 Matrix designs are balanced exactly 
 For each batch - by – strength – by – package  
combination is not tested , strength – by-package 
combination should be tested at least for 2 batches  
 Unless there are manufacturing restrictions such as 
batch ×strength×package combination only more than 
3 strengths there is a combination. 
CONCLUSION 
 In many situations matrix designs are applicable generally 
for stable products 1/3 matrix on time readily acceptable .2 
basic approaches when analyzing data  from a matrixed 
design . There  are several methods used to evaluate and 
compare potential designs.  
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